Back to Search Results
FGCL-4592
FGCL-4592-060, A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis.
The purpose of this study is to find out if the experimental drug roxadustat (also known as FG-4592) is safe and effective for treating anemia in people with chronic kidney disease who are not on dialysis.
Principal Investigator: Dr. Gary Shaw, MD
Contact: Research Department: Suzanne VanAlstyne (231) 487-3157
IRB Number: 2015-02-001
clinicaltrials.gov: 02174627
More Information: